The global Immune Cell Engineering Market is estimated to be valued at US$ 2.82 Bn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Immune cell engineering involves several techniques to genetically modify immune cells such as T cells and NK cells in order to enhance their ability to recognize and attack cancer cells. Some of the key techniques used in immune cell engineering are chimeric antigen receptor (CAR) T-cell therapy and T-cell receptor (TCR) therapy. CAR T-cell therapy is one of the most promising areas in cancer immunotherapy where T cells are collected from patient’s blood and are genetically engineered to express artificial T-cell receptors called chimeric antigen receptors (CARs) targeting specific tumor antigens. These CAR T cells are then infused back into patients to enable targeted killing of cancer cells. Immune cell engineering has potential applications in treating hematological as well as solid tumors.
Market key trends:
The immune cell engineering market is expected to witness significant growth over the forecast period owing to rising prevalence of cancer and growing number of clinical trials evaluating efficacy of immune cell therapy for cancer treatment. According to WHO, cancer burden rose to 19.3 million cases and 10 million cancer deaths in 2020. Increasing success rate of CAR T-cell therapy for hematological cancers such as lymphoma and leukemia is boosting the uptake of this technique. Continuous research to enhance the efficacy and safety of immune cell therapies for solid tumors is also driving the market growth. Emergence of new platforms such as armored CAR technology using cytokine expressing CAR T cells holds potential to expand applications of CAR T therapy beyond hematological cancers.
Porter's Analysis
Threat of new entrants: The immune cell engineering market requires high R&D investment and strict regulatory norms which act as a barrier for new companies.
Bargaining power of buyers: The presence of many immune cell engineering solution providers gives buyers higher bargaining power in terms of price and quality.
Bargaining power of suppliers: Key raw material suppliers enjoy bargaining power due to their indispensability and forming collaborations with big players.
Threat of new substitutes: Threat from substitutes is low as immune cell engineering has limited substitutes for advanced therapeutic applications.
Competitive rivalry: The immune cell engineering market is highly competitive with major players investing heavily in R&D.
Key Takeaways
The Global Immune Cell Engineering Market Demand is expected to witness high growth, exhibiting a CAGR of 22% over the forecast period, due to increasing demand for engineered immune cells for cancer immunotherapy and cell replacement therapies.
North America dominated the market in 2023, accounting for over 40% ofglobal revenue. High adoption of CAR T-cell therapy for cancer treatment along with the presence of key players drives market growth in the region.Asia Pacific is poised to be the fastest growingregion, owing to increasing investments by pharmaceutical companies and favorable government policies.
Key players operating in the immune cell engineeringmarket are Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Lonza Group, Miltenyi Biotec, Takara Bio Group, CellGenix GmbH, FUJIFILM Irvine Scientific, Agilent Technologies, Bio-Techne Corporation, Bio-Rad Laboratories, BD, Charles River Laboratories, Creative Bioarray, Sartorius AG, Novogene Corporation, AGC Biologics, Catalent, WuXi AppTec, ReachBio LLC.
